Development of Drug for Ulcerative Colitis to Be Discontinued, Company Reports

Development of Drug for Ulcerative Colitis to Be Discontinued, Company Reports
Belgium-based Galapagos NV has announced it is discontinuing its clinical development of drug candidate GLPG1205 for ulcerative colitis because an important part of the clinical trial — endpoints for efficacy — were not met. The ORIGIN Phase 2a clinical trial with GLPG1205 in patients with ulcerative colitis received good feedback on pharmacokinetics, tolerability, and safety, the company reported in a press

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *